Eureka initiates trial to evaluate ET140203 ARTEMIS T Cell Therapy in HCC

This article was originally published here

ET140203 follows on the experience gained from Eureka’s study of ET140202. ET140202 and ET140203 utilize Eureka’s proprietary ARTEMIS cell receptor platform engineered with a TCR-mimic antibody to target

The post Eureka initiates trial to evaluate ET140203 ARTEMIS T Cell Therapy in HCC appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply